223 related articles for article (PubMed ID: 34718369)
21. Erinacine Facilitates the Opening of the Mitochondrial Permeability Transition Pore Through the Inhibition of the PI3K/ Akt/GSK-3β Signaling Pathway in Human Hepatocellular Carcinoma.
Zhou LJ; Mo YB; Bu X; Wang JJ; Bai J; Zhang JW; Cheng AB; Ma JH; Wang YW; Xie YX
Cell Physiol Biochem; 2018; 50(3):851-867. PubMed ID: 30355923
[TBL] [Abstract][Full Text] [Related]
22. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
[TBL] [Abstract][Full Text] [Related]
23. Small nucleolar RNA ACA11 promotes proliferation, migration and invasion in hepatocellular carcinoma by targeting the PI3K/AKT signaling pathway.
Wu L; Zheng J; Chen P; Liu Q; Yuan Y
Biomed Pharmacother; 2017 Jun; 90():705-712. PubMed ID: 28419966
[TBL] [Abstract][Full Text] [Related]
24. TIPE‑2 suppresses growth and aggressiveness of hepatocellular carcinoma cells through downregulation of the phosphoinositide 3‑kinase/AKT signaling pathway.
Wang L; Chen C; Feng S; Tian J
Mol Med Rep; 2018 May; 17(5):7017-7026. PubMed ID: 29568863
[TBL] [Abstract][Full Text] [Related]
25. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of TMEM16A suppresses growth and induces apoptosis in hepatocellular carcinoma.
Zhang C; Liu J; Han Z; Cui X; Peng D; Xing Y
Int J Clin Oncol; 2020 Jun; 25(6):1145-1154. PubMed ID: 32240440
[TBL] [Abstract][Full Text] [Related]
27. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
Zhang R; Lian Y; Xie K; Cai Y; Pan Y; Zhu Y
Bioengineered; 2021 Dec; 12(2):9162-9173. PubMed ID: 34696683
[TBL] [Abstract][Full Text] [Related]
28. MARCH1 encourages tumour progression of hepatocellular carcinoma via regulation of PI3K-AKT-β-catenin pathways.
Xie L; Dai H; Li M; Yang W; Yu G; Wang X; Wang P; Liu W; Hu X; Zhao M
J Cell Mol Med; 2019 May; 23(5):3386-3401. PubMed ID: 30793486
[TBL] [Abstract][Full Text] [Related]
29. Isoliquiritigenin inhibits the proliferation, migration and metastasis of Hep3B cells via suppressing cyclin D1 and PI3K/AKT pathway.
Huang Y; Liu C; Zeng WC; Xu GY; Wu JM; Li ZW; Huang XY; Lin RJ; Shi X
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840737
[TBL] [Abstract][Full Text] [Related]
30. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
Song W; Zhang J; Xia Q; Sun M
Cell Cycle; 2019 Nov; 18(22):3177-3188. PubMed ID: 31564201
[No Abstract] [Full Text] [Related]
31. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.
Hsieh YH; Hsieh SC; Lee CH; Yang SF; Cheng CW; Tang MJ; Lin CL; Lin CL; Chou RH
Oncotarget; 2015 Oct; 6(33):34859-74. PubMed ID: 26472188
[TBL] [Abstract][Full Text] [Related]
32. FAM134B induces tumorigenesis and epithelial-to-mesenchymal transition via Akt signaling in hepatocellular carcinoma.
Zhang ZQ; Chen J; Huang WQ; Ning D; Liu QM; Wang C; Zhang L; Ren L; Chu L; Liang HF; Fan HN; Zhang BX; Chen XP
Mol Oncol; 2019 Apr; 13(4):792-810. PubMed ID: 30556279
[TBL] [Abstract][Full Text] [Related]
33. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D; Ruan Y; Zhou X
Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
[TBL] [Abstract][Full Text] [Related]
34. microRNA-1914, which is regulated by lncRNA DUXAP10, inhibits cell proliferation by targeting the GPR39-mediated PI3K/AKT/mTOR pathway in HCC.
Sun L; Wang L; Chen T; Yao B; Wang Y; Li Q; Yang W; Liu Z
J Cell Mol Med; 2019 Dec; 23(12):8292-8304. PubMed ID: 31576658
[TBL] [Abstract][Full Text] [Related]
35. LINC00963 promotes hepatocellular carcinoma progression by activating PI3K/AKT pathway.
Wu JH; Tian XY; An QM; Guan XY; Hao CY
Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1645-1652. PubMed ID: 29630107
[TBL] [Abstract][Full Text] [Related]
36. Apatinib potentiates irradiation effect via suppressing PI3K/AKT signaling pathway in hepatocellular carcinoma.
Liao J; Jin H; Li S; Xu L; Peng Z; Wei G; Long J; Guo Y; Kuang M; Zhou Q; Peng S
J Exp Clin Cancer Res; 2019 Nov; 38(1):454. PubMed ID: 31694662
[TBL] [Abstract][Full Text] [Related]
37. CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway.
Liu YM; Cao Y; Zhao PS; Wu LY; Lu YM; Wang YL; Zhao JF; Liu XG
Int J Biol Sci; 2022; 18(2):637-651. PubMed ID: 35002514
[No Abstract] [Full Text] [Related]
38. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
Wu WL; Wang WY; Yao WQ; Li GD
Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
[TBL] [Abstract][Full Text] [Related]
39. Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.
Zhang MH; Niu H; Li Z; Huo RT; Wang JM; Liu J
Cancer Biomark; 2018; 23(1):33-43. PubMed ID: 29991125
[TBL] [Abstract][Full Text] [Related]
40. SNORD126 promotes HCC and CRC cell growth by activating the PI3K-AKT pathway through FGFR2.
Fang X; Yang D; Luo H; Wu S; Dong W; Xiao J; Yuan S; Ni A; Zhang KJ; Liu XY; Chu L
J Mol Cell Biol; 2017 Jun; 9(3):243-255. PubMed ID: 27913571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
